Molecular Therapy· Satrusal·收录于· 6 天前
Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage
Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

来源:Molecular Therapy · doi.org